SPYRE THERAPEUTICS INC (SYRE) Forecast, Price Target & Analyst Ratings

NASDAQ:SYRE • US00773J2024

Current stock price

43.95 USD
-0.12 (-0.27%)
At close:
44.97 USD
+1.02 (+2.32%)
Pre-Market:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SPYRE THERAPEUTICS INC (SYRE).

Forecast Snapshot

Consensus Price Target

Price Target
$59.74
+ 35.93% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.68
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
89.52%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$59.74
Upside
+ 35.93%
From current price of $43.95 to mean target of $59.74, Based on 21 analyst forecasts
Low
$47.47
Median
$60.69
High
$73.50

Price Target Revisions

1 Month
3.80%
3 Months
12.44%

Price Target Summary

21 Wall Street analysts provided a forecast for the next 12 months for SYRE. The average price target is 59.74 USD. This implies a price increase of 35.93% is expected in the next year compared to the current price of 43.95.
The average price target has been revised upward by 12.44% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

SYRE Current Analyst RatingSYRE Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

SYRE Historical Analyst RatingsSYRE Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
89.52%
SYRE was analyzed by 21 analysts. The buy percentage consensus is at 90. So analysts seem to be very confident about SYRE.
In the previous month the buy percentage consensus was at a similar level.
SYRE was analyzed by 21 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-16BTIGReiterate Buy -> Buy
2026-02-20BTIGReiterate Buy -> Buy
2026-02-20Wells FargoMaintains Overweight -> Overweight
2026-01-16BTIGReiterate Buy -> Buy
2025-12-18MizuhoInitiate Outperform
2025-12-17CitigroupInitiate Buy
2025-12-01Jones TradingUpgrade Hold -> Buy
2025-09-26Deutsche BankInitiate Buy
2025-09-16BTIGReiterate Buy -> Buy
2025-04-08Leerink PartnersInitiate Outperform
2024-12-11Jones TradingInitiate Hold
2024-11-13BairdMaintains Outperform -> Outperform
2024-10-25GuggenheimMaintains Buy -> Buy
2024-09-04WedbushInitiate Outperform
2024-07-16Evercore ISI GroupInitiate Outperform
2024-05-13Wells FargoMaintains Overweight -> Overweight
2024-05-10BTIGMaintains Buy -> Buy
2024-05-02BairdInitiate Outperform
2024-03-26StifelReiterate Buy -> Buy
2024-03-01Wells FargoUpgrade Equal-Weight -> Overweight
2023-12-20BTIGInitiate Buy
2023-12-18StifelMaintains Buy -> Buy
2023-12-11GuggenheimInitiate Buy
2023-12-11JefferiesInitiate Buy
2023-11-29TD CowenInitiate Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.68
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-13.28%
Number of Analysts
16

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-16.73%
EPS (3 Months)
0.89%

Next Earnings Summary

SYRE is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.68 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
SYRE revenue by date.SYRE revenue by date.
18.74M2.33M
-87.57%		886K
-61.97%		2.142M
-100.00%		27.44M12.665M
-53.84%		201.98M
1,494.79%		780.85M
286.60%		1.689B
116.30%
EBITDA
YoY % growth
SYRE ebitda by date.SYRE ebitda by date.
-64.07M
20.39%		-83.21M
-29.87%		-116.868M
-40.45%		-193.248M
-78.46%		-216.443M
-5.27%		-251.393M
-14.50%		-275.141M
-9.45%		-291.733M
-6.03%		-361.353M
-23.86%		-153.97M
57.39%		N/AN/AN/A
EBIT
YoY % growth
SYRE ebit by date.SYRE ebit by date.
-65.65M
19.43%		-84.78M
-29.14%		-117.612M
-38.73%		-205.549M
-77.33%		-219.129M
-5.27%		-264.846M
-20.62%		-301.324M
-13.77%		-338.509M
-12.34%		-389.982M
-15.21%		-427.778M
-9.69%		-400.676M
6.34%		21.012M
105.24%		832.69M
3,862.93%
Operating Margin
SYRE operating margin by date.SYRE operating margin by date.
-350.32%-3,638.63%-13,274.49%-9,596.12%N/AN/AN/AN/A-1,421.22%-3,377.64%-198.37%2.69%49.30%
EPS
YoY % growth
SYRE eps by date.SYRE eps by date.
-25.00
37.89%		-25.25
-1.00%		-59.89
-137.19%		-4.45
92.94%		-2.17
47.52%		-2.99
-34.90%		-3.22
-7.60%		-3.45
-7.17%		-3.65
-5.60%		-3.59
1.54%		-2.68
25.39%		2.38
188.70%		11.16
369.67%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.68
-13.28%		-0.73
5.23%		-0.67
-344.19%		-0.69
1.71%		-0.27
60.68%		-0.30
58.91%		-0.32
52.54%		-0.33
51.82%
Revenue
Q2Q % growth		N/AN/AN/AN/A
EBITDA
Q2Q % growth		-58.585M-59.062M-60.694M
-8.38%		-62.832M
-3.40%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-61.404M
-14.63%		-64.686M
-24.55%		-66.365M
-16.43%		-70.516M
-12.20%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

SYRE Yearly Revenue VS EstimatesSYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2029 2030 2031 2032 2033 500M 1B 1.5B
SYRE Yearly EPS VS EstimatesSYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150 -200

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-15.87%
EPS Next 5 Year
-10.10%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-10.01%
EBIT Next 5 Year
5.34%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

SPYRE THERAPEUTICS INC / SYRE Forecast FAQ

What is the price target for SYRE stock?

21 analysts have analysed SYRE and the average price target is 59.74 USD. This implies a price increase of 35.93% is expected in the next year compared to the current price of 43.95.

When does SPYRE THERAPEUTICS INC (SYRE) report earnings?

SPYRE THERAPEUTICS INC (SYRE) will report earnings on 2026-05-06.

Can you provide the consensus estimates for SPYRE THERAPEUTICS INC next earnings?

The consensus EPS estimate for the next earnings of SPYRE THERAPEUTICS INC (SYRE) is -0.68 USD and the consensus revenue estimate is 0 USD.

How many analysts cover SPYRE THERAPEUTICS INC (SYRE) stock?

The number of analysts covering SPYRE THERAPEUTICS INC (SYRE) is 21.